A potential role for imatinib and other small molecule tyrosine kinase inhibitors in the treatment of systemic and localized sclerosis

Journal of the American Academy of Dermatology

Volumn 59, Issue 4, 2008, Pages 654-658

  Bibi, Yuval ^a,b   Gottlieb, Alice B ^b  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMATINIB; PROTEIN TYROSINE KINASE INHIBITOR;

ASCITES; CLINICAL TRIAL; DRUG MECHANISM; EDEMA; HUMAN; HYPEREOSINOPHILIC SYNDROME; KIDNEY FIBROSIS; LOCALIZED SCLERODERMA; LUNG EDEMA; LUNG FIBROSIS; MASTOCYTOSIS; MORPHEA; MUSCLE CRAMP; MYELOID LEUKEMIA; NAUSEA; NEUTROPENIA; PERICARDIAL EFFUSION; PLEURA EFFUSION; PRIORITY JOURNAL; RAYNAUD PHENOMENON; REVIEW; SKIN FIBROSIS; SYNDROME CREST; SYSTEMIC SCLEROSIS; THROMBOCYTOPENIA; VOMITING;

FIBROSIS; HUMANS; PIPERAZINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES; RAYNAUD DISEASE; SCLERODERMA, LOCALIZED; SCLERODERMA, SYSTEMIC; SKIN;

EID: 51349094610     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaad.2008.04.034     Document Type: Review

References (40)

1. Druker B.J., Tamura S., Buchdunger E., Ohno S., Segal G.M., Fanning S., et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 2 (1996) 561-566
2. Heinrich M.C., Griffith D.J., Druker B.J., Wait C.L., Ott K.A., and Zigler A.J. Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Blood 96 (2000) 925-932
3. Seggewiss R., Lore K., Greiner E., Magnusson M.K., Price D.A., Douek D.C., et al. Imatinib inhibits T-cell receptor-mediated T-cell proliferation and activation in a dose-dependent manner. Blood 105 (2005) 2473-2479
4. Buchdunger E., Cioffi C.L., Law N., Stover D., Ohno-Jones S., Druker B.J., et al. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther 295 (2000) 139-145
5. Sankhala K.K., and Papadopoulos K.P. Future options for imatinib mesilate-resistant tumors. Expert Opin Investig Drugs 16 (2007) 1549-1560
6. Deininger M.W., O'Brien S.G., Ford J.M., and Druker B.J. Practical management of patients with chronic myeloid leukemia receiving imatinib. J Clin Oncol 21 (2003) 1637-1647
7. Schaller J.L., and Burkland G.A. Case report: rapid and complete control of idiopathic hypereosinophilia with imatinib mesylate. MedGenMed 3 (2001) 9
8. Ault P., Cortes J., Koller C., Kaled E.S., and Kantarjian H. Response of idiopathic hypereosinophilic syndrome to treatment with imatinib mesylate. Leuk Res 26 (2002) 881-884
9. Gleich G.J., Leiferman K.M., Pardanani A., Tefferi A., and Butterfield J.H. Treatment of hypereosinophilic syndrome with imatinib mesilate. Lancet 359 (2002) 1577-1578
10. Pardanani A., Reeder T., Porrata L.F., Li C.Y., Tazelaar H.D., Baxter E.J., et al. Imatinib therapy for hypereosinophilic syndrome and other eosinophilic disorders. Blood 101 (2003) 3391-3397
11. Cools J., DeAngelo D.J., Gotlib J., Stover E.H., Legare R.D., Cortes J., et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med 348 (2003) 1201-1214
12. Martinelli G., Malagola M., Ottaviani E., Rosti G., Trabacchi E., and Baccarani M. Imatinib mesylate can induce complete molecular remission in FIP1L1-PDGFR-a positive idiopathic hypereosinophilic syndrome. Haematologica 89 (2004) 236-237
13. Pardanani A., Brockman S.R., Paternoster S.F., Flynn H.C., Ketterling R.P., Lasho T.L., et al. FIP1L1-PDGFRA fusion: prevalence and clinicopathologic correlates in 89 consecutive patients with moderate to severe eosinophilia. Blood 104 (2004) 3038-3045
14. Baccarani M., Cilloni D., Rondoni M., Ottaviani E., Messa F., Merante S., et al. The efficacy of imatinib mesylate in patients with FIP1L1-PDGFRalpha-positive hypereosinophilic syndrome: results of a multicenter prospective study. Haematologica 92 (2007) 1173-1179
15. Orfao A., Garcia-Montero A.C., Sanchez L., Escribano L., and REMA. Recent advances in the understanding of mastocytosis: the role of KIT mutations. Br J Haematol 138 (2007) 12-30
16. Trojanowska M. What did we learn by studying scleroderma fibroblasts?. Clin Exp Rheumatol 22 Suppl (2004) S59-S63
17. Klareskog L., Gustafsson R., Scheynius A., and Hallgren R. Increased expression of platelet-derived growth factor type B receptors in the skin of patients with systemic sclerosis. Arthritis Rheum 33 (1990) 1534-1541
18. Yamakage A., Kikuchi K., Smith E.A., LeRoy E.C., and Trojanowska M. Selective upregulation of platelet-derived growth factor alpha receptors by transforming growth factor beta in scleroderma fibroblasts. J Exp Med 175 (1992) 1227-1234
19. Zheng X.Y., Zhang J.Z., Tu P., and Ma S.Q. Expression of platelet-derived growth factor B-chain and platelet-derived growth factor beta-receptor in fibroblasts of scleroderma. J Dermatol Sci 18 (1998) 90-97
20. Verrecchia F., Mauviel A., and Farge D. Transforming growth factor-beta signaling through the Smad proteins: role in systemic sclerosis. Autoimmun Rev 5 (2006) 563-569
21. Baroni S.S., Santillo M., Bevilacqua F., Luchetti M., Spadoni T., Mancini M., et al. Stimulatory autoantibodies to the PDGF receptor in systemic sclerosis. N Engl J Med 354 (2006) 2667-2676
22. Svegliati S., Olivieri A., Campelli N., Luchetti M., Poloni A., Trappolini S., et al. Stimulatory autoantibodies to PDGF receptor in patients with extensive chronic graft-versus-host disease. Blood 110 (2007) 237-241
23. Sambo P., Baroni S.S., Luchetti M., Paroncini P., Dusi S., Orlandini G., et al. Oxidative stress in scleroderma: maintenance of scleroderma fibroblast phenotype by the constitutive up-regulation of reactive oxygen species generation through the NADPH oxidase complex pathway. Arthritis Rheum 44 (2001) 2653-2664
24. Svegliati S., Cancello R., Sambo P., Luchetti M., Paroncini P., Orlandini G., et al. Platelet-derived growth factor and reactive oxygen species (ROS) regulate Ras protein levels in primary human fibroblasts via ERK1/2: amplification of ROS and Ras in systemic sclerosis fibroblasts. J Biol Chem 280 (2005) 36474-36482
25. Lozano E., Segarra M., and Cid M.C. Stimulatory autoantibodies to the PDGF receptor in scleroderma. N Engl J Med 355 (2006) 1278-1279
26. Abdollahi A., Li M., Ping G., Plathow C., Domhan S., Kiessling F., et al. Inhibition of platelet-derived growth factor signaling attenuates pulmonary fibrosis. J Exp Med 201 (2005) 925-935
27. Aono Y., Nishioka Y., Inayama M., Ugai M., Kishi J., Uehara H., et al. Imatinib as a novel antifibrotic agent in bleomycin-induced pulmonary fibrosis in mice. Am J Respir Crit Care Med 171 (2005) 1279-1285
28. Vuorinen K., Gao F., Oury T.D., Kinnula V.L., and Myllarniemi M. Imatinib mesylate inhibits fibrogenesis in asbestos-induced interstitial pneumonia. Exp Lung Res 33 (2007) 357-373
29. Ghofrani H.A., Seeger W., and Grimminger F. Imatinib for the treatment of pulmonary arterial hypertension. N Engl J Med 353 (2005) 1412-1413
30. Schermuly R.T., Dony E., Ghofrani H.A., Pullamsetti S., Savai R., Roth M., et al. Reversal of experimental pulmonary hypertension by PDGF inhibition. J Clin Invest 115 (2005) 2811-2821
31. Ludewig D., Kosmehl H., Sommer M., Bohmer F.D., and Stein G. PDGF receptor kinase blocker AG1295 attenuates interstitial fibrosis in rat kidney after unilateral obstruction. Cell Tissue Res 299 (2000) 97-103
32. Schellings M.W., Baumann M., van Leeuwen R.E., Duisters R.F., Janssen S.H., Schroen B., et al. Imatinib attenuates end-organ damage in hypertensive homozygous TGR(mRen2)27 rats. Hypertension 47 (2006) 467-474
33. Ponten A., Folestad E.B., Pietras K., and Eriksson U. Platelet-derived growth factor D induces cardiac fibrosis and proliferation of vascular smooth muscle cells in heart-specific transgenic mice. Circ Res 97 (2005) 1036-1045
34. Distler J.H., Jungel A., Huber L.C., Schulze-Horsel U., Zwerina J., Gay R.E., et al. Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis. Arthritis Rheum 56 (2007) 311-322
35. Kallenberg C.G. Early detection of connective tissue disease in patients with Raynaud's phenomenon. Rheum Dis Clin North Am 16 (1990) 11-30
36. Rajkumar V.S., Sundberg C., Abraham D.J., Rubin K., and Black C.M. Activation of microvascular pericytes in autoimmune Raynaud's phenomenon and systemic sclerosis. Arthritis Rheum 42 (1999) 930-941
37. Furspan P.B., Mayes M.D., and Freedman R.R. Effect of temperature and modulators of protein tyrosine kinase activity on the reactivity of isolated venules in secondary Raynaud's phenomenon. J Rheumatol 28 (2001) 2263-2268
38. Furspan P.B., Chatterjee S., and Freedman R.R. Increased tyrosine phosphorylation mediates the cooling-induced contraction and increased vascular reactivity of Raynaud's disease. Arthritis Rheum 50 (2004) 1578-1585
39. Zhou X., Tan F.K., Stivers D.N., and Arnett F.C. Microsatellites and intragenic polymorphisms of transforming growth factor beta and platelet-derived growth factor and their receptor genes in Native Americans with systemic sclerosis (scleroderma): a preliminary analysis showing no genetic association. Arthritis Rheum 43 (2000) 1068-1073
40. US National Institutes of Health. ClinicalTrials.gov. Available at: http://www.clinicaltrials.gov. Accessed May 27, 2008